{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T11:46:59.290120+00:00","company":{"ticker":"PAHC","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP"},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"7dd2ce3b7b9bf5311cb1310a1abaf4279fe8b648","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.59","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$24.0 million","period_text":"third quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$383.5 million"},"claim":"PHIBRO ANIMAL HEALTH CORP reported third quarter ended March 31, 2026 results: revenue $383.5 million, net income $24.0 million, EPS $0.59. Guidance reaffirmed.","evidence_excerpt":"guidance for the year ending June 30, 2026. ​ Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025): ​ - Net sales of $383.5 million, an increase of $35.7 million, or 10% - Net income of $24.0 million, an increase of $3.1 million, or 15% - Diluted earnings per share of $0.59, an increase of $0.08, or 16% -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-056316","anchor_url":"https://secwatch.observer/filing/0001104659-26-056316#claim-7dd2ce3b7b9bf5311cb1310a1abaf4279fe8b648","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/0001104659-26-056316-index.htm"},{"fact_type":"debt_financing","fact_key":"7f08ad99b7ee4490267c3897a9c7b077b847cd63","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-04-30T23:59:59+00:00","payload":{"counterparty":"Coöperatieve Rabobank U.A., New York Branch","effective_date":"2026-04-28","event":"amendment","instrument_type":"revolving_credit","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"aggregate commitment of $435,000,000"},"claim":"PHIBRO ANIMAL HEALTH CORP amended revolving credit of aggregate commitment of $435,000,000 with Coöperatieve Rabobank U.A., New York Branch.","evidence_excerpt":"1, the revolving credit\ncommitment available to the Company under the Original Credit Agreement has increased by $125,000,000, from $310,000,000 to an aggregate\ncommitment of $435,000,000. The foregoing description of Amendment No. 1 does\nnot purport to be complete and is qualified in its entirety by reference to Amendment No. 1, a copy of which has been filed as","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-052956","anchor_url":"https://secwatch.observer/filing/0001104659-26-052956#claim-7f08ad99b7ee4490267c3897a9c7b077b847cd63","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926052956/0001104659-26-052956-index.htm"},{"fact_type":"material_agreement","fact_key":"107bf989eb5fde663d8bd903fddeffc932e1eb53","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1","agreement_type":"credit_facility","counterparty":"Coöperatieve Rabobank U.A., New York Branch","effective_date":"2026-04-28","item_codes_triggered":["1.01"],"value_text":"$125,000,000"},"claim":"PHIBRO ANIMAL HEALTH CORP amended Amendment No. 1 with Coöperatieve Rabobank U.A., New York Branch valued at $125,000,000 (effective 2026-04-28).","evidence_excerpt":"On April 28, 2026, Phibro Animal Health Corporation (the “Company”) entered into Amendment No. 1 to its Credit Agreement (“Amendment No. 1”) with Coöperatieve Rabobank U.A., New York Branch, as administrative agent, collateral agent and L/C issuer, and each lender from time to time party thereto, which amends the Credit Agreement, dated as of July 3, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-052956","anchor_url":"https://secwatch.observer/filing/0001104659-26-052956#claim-107bf989eb5fde663d8bd903fddeffc932e1eb53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926052956/0001104659-26-052956-index.htm"},{"fact_type":"executive_change","fact_key":"28b53e00e6","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2025-01-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-21","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joyce J. Lee was appointed as Class II director at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"The Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Corporation”) appointed Joyce J. Lee as a Class II director of the Corporation, effective January 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-005659","anchor_url":"https://secwatch.observer/filing/0001104659-25-005659#claim-28b53e00e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465925005659/0001104659-25-005659-index.htm"},{"fact_type":"executive_change","fact_key":"a480969672","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"promoted","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"President, North American Region","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Todd Armstrong was appointed as President, North American Region at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"Todd Armstrong, currently serving as Vice President of the US Ruminant Business since 2020, will be promoted to President, North American Region, effective January 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-116790","anchor_url":"https://secwatch.observer/filing/0001104659-24-116790#claim-a480969672","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924116790/0001104659-24-116790-index.htm"},{"fact_type":"executive_change","fact_key":"3f345e33c3","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"retiring","action_category":"departure","departure_tone":"retirement","effective_date":"2024-12-31","interim":false,"role":"President, North America Region","role_category":"other_named_officer","successor_name":"Todd Armstrong","successor_named":true},"claim":"Rob Aukerman departed as President, North America Region at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"On November 7, 2024, Phibro Animal Health Corporation (the “Company”) was notified by Rob Aukerman that he will be retiring from his position as President, North America Region of the Company effective December 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-116790","anchor_url":"https://secwatch.observer/filing/0001104659-24-116790#claim-3f345e33c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924116790/0001104659-24-116790-index.htm"},{"fact_type":"earnings_release","fact_key":"71cdb3846c539fcecb7d0ba9dd9fa78ed558c5a5","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"$0.17 to $0.30","guidance_signal":"unknown","item_codes_triggered":["2.02"],"net_income_text":"$7 million to $12 million","period_text":"the fiscal year ending June 30, 2024","report_date":"2024-05-08","result_type":"guidance_update","revenue_text":"$980 million to $1.020 billion"},"claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal year ending June 30, 2024 results: revenue $980 million to $1.020 billion, net income $7 million to $12 million, EPS $0.17 to $0.30.","evidence_excerpt":"We affirm our previously issued fiscal year 2024 guidance for the following measures: ​ – Net sales of $980 million to $1.020 billion – Adjusted EBITDA of $106 million to $112 million – Adjusted net income of $42 million to $47 million – Adjusted diluted EPS of $1.04 to $1.16 – Adjusted effective tax rate of 28% to 30% ​ We have updated our fiscal year 2024 guidance for the following measures: ​ - Net income of $7 million to $12 million - Diluted EPS of $0.17 to $0.30","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-007371","anchor_url":"https://secwatch.observer/filing/0001558370-24-007371#claim-71cdb3846c539fcecb7d0ba9dd9fa78ed558c5a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm"},{"fact_type":"earnings_release","fact_key":"04e2cd6410c09334d8f94a83cfbfb832ea3daad3","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"$0.21","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$8.4 million","period_text":"the fiscal quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$263.2 million"},"claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended March 31, 2024 results: revenue $263.2 million, net income $8.4 million, EPS $0.21.","evidence_excerpt":"Net sales of $263.2 million, an increase of $17.6 million, or 7% - Net income of $8.4 million, a decrease of $1.6 million - Diluted earnings per share of $0.21, a decrease of $0.04","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-007371","anchor_url":"https://secwatch.observer/filing/0001558370-24-007371#claim-04e2cd6410c09334d8f94a83cfbfb832ea3daad3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm"},{"fact_type":"material_agreement","fact_key":"d7c1e07f303b3631eddedbdc8ad0fa4701d0ea0d","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Debt Commitment Letter","agreement_type":"credit_facility","counterparty":"Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A.","effective_date":"2024-04-28","item_codes_triggered":["1.01"],"value_text":"$325 million senior secured incremental first lien term loan facility"},"claim":"PHIBRO ANIMAL HEALTH CORP entered into Debt Commitment Letter with Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A. valued at $325 million senior secured incremental first lien term loan facility (effective 2024-04-28).","evidence_excerpt":"Phibro entered into a debt commitment letter (the “Commitment Letter”), dated as of April 28, 2024, with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), Compeer Financial, PCA (“Compeer”) and Citibank, N.A. (“Citibank” and, collectively with Rabobank and Compeer, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325 million (the “Incremental Term Facility”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-053265","anchor_url":"https://secwatch.observer/filing/0001104659-24-053265#claim-d7c1e07f303b3631eddedbdc8ad0fa4701d0ea0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924053265/0001104659-24-053265-index.htm"},{"fact_type":"material_agreement","fact_key":"74d5de90fc77829dcd2bd7ea763c2acd5143cd80","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase and Sale Agreement","agreement_type":"asset_purchase","counterparty":"Zoetis Inc.","effective_date":"2024-04-28","item_codes_triggered":["1.01"],"value_text":"$350 million"},"claim":"PHIBRO ANIMAL HEALTH CORP entered into Purchase and Sale Agreement with Zoetis Inc. valued at $350 million (effective 2024-04-28).","evidence_excerpt":"On April 28, 2024, Phibro Animal Health Corporation, a Delaware corporation (“Phibro Animal Health”), and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of Phibro Animal Health (together with Phibro Animal Health, “Phibro”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-053265","anchor_url":"https://secwatch.observer/filing/0001104659-24-053265#claim-74d5de90fc77829dcd2bd7ea763c2acd5143cd80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924053265/0001104659-24-053265-index.htm"},{"fact_type":"earnings_release","fact_key":"b9bd0af051986bc74e533e0bdc243ca544b2be95","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-02-07T23:59:59+00:00","payload":{"eps_text":"$0.03","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$1.3 million","period_text":"the fiscal quarter ended December 31, 2023","report_date":"2024-02-07","result_type":"reported_results","revenue_text":"$249.9 million"},"claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended December 31, 2023 results: revenue $249.9 million, net income $1.3 million, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"guidance for the year ending June 30, 2024. ​ Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) ​ - Net sales of $249.9 million, an increase of $5.3 million, or 2% - Net income of $1.3 million, a decrease of $5.9 million - Diluted earnings per share of $0.03, a decrease of $0.15 - Adjusted EBITDA of $29.5","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-000864","anchor_url":"https://secwatch.observer/filing/0001558370-24-000864#claim-b9bd0af051986bc74e533e0bdc243ca544b2be95","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm"},{"fact_type":"executive_change","fact_key":"e77d3c3ffc","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"stepped down as interim CFO","action_category":"role_change","departure_tone":"routine","effective_date":"2024-02-09","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":"Glenn C. David","successor_named":true},"claim":"Richard Johnson changed role as interim Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-010954","anchor_url":"https://secwatch.observer/filing/0001104659-24-010954#claim-e77d3c3ffc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm"},{"fact_type":"executive_change","fact_key":"29a2ba7784","cik":1069899,"ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-09","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Glenn C. David was appointed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-010954","anchor_url":"https://secwatch.observer/filing/0001104659-24-010954#claim-29a2ba7784","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm"}]}